Besides NADPH oxidase, uncoupling eNOS has been identified as an important source of ROS and its expression was significantly increased at both messenger RNA (mRNA) and protein levels in AIA rats. Similarly, via nitration of superoxide dismutase (SOD), peroxynitrite inactivates the enzyme, leading to diminished antioxidant cellular defense mechanisms and increase in superoxide levels [29, 30]. In this study, we investigated the effects of STA on the Hcy-induced endothelial dysfunction and with the emphasis on its role in eNOS uncoupling and the underlying mechanism. Negative regulation of NO synthesis can also be mediated through overproduction of methylated arginine analogues such as ADMA. Elevated superoxide levels are also the result of peroxynitrite action-induced protein phosphatase 2A (PP2A) activation, which leads in turn to the dephosphorylation of eNOS and therefore decrease in enzyme activity and subsequent NO generation [31, 32]. You, “Autoantibodies to dsDNA cross-react with the arginine-glycine-rich domain of heterogeneous nuclear ribonucleoprotein A2 (hnRNP A2) and promote methylation of hnRNP A2,”, I. E. Bultink, T. Teerlink, J. Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4. In the latter study by Spinelli et al., besides a decrease in ADMA plasma concentrations, anti-TNF therapy restored circulating endothelial progenitor cell levels, although a not significant increase of FMD was observed. Many lines of evidence indicate that oxidative degeneration of BH4 by ROS leads to the eNOS uncoupling, reduction in NO bioavailability, and increased reactive oxygen species production [73, 74]. Since reduction in L-arginine availability has emerged as an important mechanism underlying decreased NO bioavailability and endothelial dysfunction, many clinical and experimental studies during the past decade have shown beneficial effects of L-arginine supplementation in both animal studies and humans [104–112]. ( 145 ) confirmed the improvement … In accordance with results from animal studies, an increase in plasma arginase activity with a significant decrease in arginine bioavailability was reported in patients with RA [55]. Both superoxide and peroxynitrite also oxidize low-density lipoproteins (LDL) forming oxidized LDL (ox-LDL), which in turn through the scavenger receptor, lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), downregulates the enzyme expression. Inflammation, oxidative stress, and the vascular endothelium in obstructive sleep apnea. Although it is clearly recognized that systemic inflammation with increased proinflammatory cytokine production induces arginase expression, the exact regulatory mechanisms of enzyme activity or gene expression in the endothelial cells still remain elusive. Therefore, further studies are needed to clarify why patients with anti-nuclear antibodies have less pronounced subclinical atherosclerosis, even having more systemic and severe course of disease, interspersed with episodes of acute disease flares. Induction of sensory long-term facilitation in the carotid body by intermittent hypoxia: implications for recurrent apneas. A. Vita and J. F. Keaney Jr., “Endothelial function: a barometer for cardiovascular risk?”, J. P. Halcox, A. E. Donald, E. Ellins et al., “Endothelial function predicts progression of carotid intima-media thickness,”, H. Brunner, J. R. Cockcroft, J. Deanfield et al., “Endothelial function and dysfunction. The effect of a curative treatment with nor-NOHA on vascular function of AIA rats was further investigated, and authors indicated that it is mediated by an increase in NOS activity and endothelium-derived hyperpolarizing factor (EDHF) production; a decrease in cyclooxygenase 2 (COX-2), thromboxane (TX), and prostaglandin I2 (PGI2) synthase and NADPH oxidase activities; and a decrease in superoxide production and secreted vascular endothelial growth factor (VEGF) levels. Studies on animals and humans have provided evidence that IFN accelerate atherosclerosis on multiple stages [149–151]. Ozaki M, Kawashima S, Yamashita T, Hirase T, Namiki M, Inoue N, Hirata K, Yasui H, Sakurai H, Yoshida Y, Masada M, Yokoyama M. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. Philippi NR, Bird CE, Marcus NJ, Olson EB, Chesler NC, Morgan BJ. Arginase also inhibits the L-arginine transport in endothelial cells further exacerbating L-arginine deficiency and downregulating NO production [133]. Mechanisms of endothelial nitric oxide synthase (eNOS) uncoupling in endothelial dysfunction. Molecular Mechanism of eNOS Uncoupling. However, the exact role of eNOS uncoupling in premature atherogenesis in rheumatic diseases is still not fully elucidated. Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations. Peroxynitrite oxidizes tetrahydrobiopterin (BH4), the eNOS cofactor to the trihydrobiopterin (BH3) radical, resulting in the eNOS uncoupling, perpetual superoxide production, and subsequent peroxynitrite formation [27]. Previously, we reported that shear stress-induced release of nitric oxide in vessels of … Indeed, a decrease in serum levels of BH4 in AIA rats compared to the control group was reported, and administration of BH4 restored endothelial function. Arginase, both isoforms I and II, is expressed in endothelial and smooth muscle cells of the vascular wall and competes with NOS for the substrate L-arginine [128]. Stachydrine protects eNOS uncoupling and ameliorates endothelial dysfunction induced by homocysteine Xinya Xie1, Zihui Zhang1, Xinfeng Wang1, Zhenyu Luo1, Baochang Lai1, Lei Xiao1*and Nanping … This eNOS uncoupling contributes to increased ROS production and decreased nitric oxide formation and consequent endothelial dysfunction . Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. However, mechanisms of accelerated atherosclerosis in these diseases, especially in the absence of traditional risk factors, still remain unclear. Copyright © 2020 Anna Łuczak et al. Endothelial dysfunction is one of the major causes for vascular complications, accompanied by oxidative stress and inflammation. Therefore, ADMA promotes superoxide production by eNOS, and the resulting oxidative stress upregulates ADMA levels [49]. BH2 binds with fairly high affinity to eNOS without supporting its catalytic activity [75]. It is thought that persistent systemic inflammation enhances CV risk through direct or indirect mechanisms leading to accentuation of existing risk pathways [12]. Endothelial nitric oxide synthase (eNOS) uncoupling is a mechanism that leads to endothelial dysfunction. Patt BT, Jarjoura D, Haddad DN, Sen CK, Roy S, Flavahan NA, Khayat RN. In animal models, ADMA levels correlated with vascular function and the degree of atherosclerosis, in humans with cholesterol levels [46, 47]. Somers VK, Dyken ME, Clary MP, Abboud FM. These findings were not confirmed by another study performed in a similar subgroup of patients treated for 18 months with either methotrexate or adalimumab [170]. Since the reduction of endothelial dysfunction seems to be possibly independent of RA disease activity, they indicated that the benefits provided by nor-NOHA are related to the direct modulation of endothelium-derived vasorelaxant pathways rather than an anti-inflammatory effect [138, 139]. GTPCH I is a rate-limiting enzyme for BH4 biosynthesis and therefore plays a major role in controlling the NOS function [71, 72]. We finally turn our attention to the inflammatory mechanisms that are also involved in the development of endothelial dysfunction and cardiovascular disease. Therefore, recent studies have shown that pharmacological supplementation of BH4 improves vascular function in patients with diabetes, essential hypertension, and hypercholesterolemia and in chronic smokers [83–95]. Fox, and N. Kashihara, “Fluvastatin reverses endothelial dysfunction and increased vascular oxidative stress in rat adjuvant-induced arthritis,”, K. M. Mäki-Petäjä, L. Day, J. Cheriyan et al., “Tetrahydrobiopterin supplementation improves endothelial function but does not alter aortic stiffness in patients with rheumatoid arthritis,”, K. M. Mäki-Petäjä, J. Cheriyan, A. D. Booth et al., “Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction,”, Y. Rikitake and J. K. Liao, “Rho GTPases, statins, and nitric oxide,”, P. Totoson, K. Maguin-Gaté, A. Prigent-Tessier et al., “Etanercept improves endothelial function via pleiotropic effects in rat adjuvant-induced arthritis,”, C. F. Spurlock III, H. M. Gass IV, C. J. Bryant, B. C. Wells, N. J. Olsen, and T. M. Aune, “Methotrexate-mediated inhibition of nuclear factor, W. Chen, L. Li, T. Brod et al., “Role of increased guanosine triphosphate cyclohydrolase-1 expression and tetrahydrobiopterin levels upon T cell activation,”, D. Popov, G. Costache, A. Georgescu, and M. Enache, “Beneficial effects of L-arginine supplementation in experimental hyperlipemia-hyperglycemia in the hamster,”, N. Pahlavani, M. Jafari, M. Rezaei et al., “L-Arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial,”, J. P. Lekakis, S. Papathanassiou, T. G. Papaioannou et al., “Oral L-arginine improves endothelial dysfunction in patients with essential hypertension,”, A. Chauhan, R. S. More, P. A. Mullins, G. Taylor, M. C. Petch, and P. M. Schofield, “Aging-associated endothelial dysfunction in humans is reversed by L-arginine,”, J. Y. Dong, L. Q. Qin, Z. Zhang et al., “Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials,”, P. Clarkson, M. R. Adams, A. J. Powe et al., “Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults,”, H. Drexler, A. M. Zeiher, K. Meinzer, and H. Just, “Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine,”, R. H. Boger, S. M. Bode-Boger, A. Mugge et al., “Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production,”, G. Siasos, D. Tousoulis, C. Vlachopoulos et al., “The impact of oral L-arginine supplementation on acute smoking-induced endothelial injury and arterial performance,”, Y. Xiong, M. F. Fru, Y. Yu, J. P. Montani, X. F. Ming, and Z. Yang, “Long term exposure to L-arginine accelerates endothelial cell senescence through arginase-II and S6K1 signaling,”, J. Rodrigues-Krause, M. Krause, I. M. G. D. Rocha, D. Umpierre, and A. P. T. Fayh, “Association of l-arginine supplementation with markers of endothelial function in patients with cardiovascular or metabolic disorders: a systematic review and meta-analysis,”, H. A. Walker, E. McGing, I. Fisher et al., “Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance,”, T. S. Alvares, C. A. Conte-Junior, J. T. Silva, and V. M. F. Paschoalin, “L-Arginine does not improve biochemical and hormonal response in trained runners after 4 weeks of supplementation,”, Z. Bahadoran, P. Mirmiran, Z. Tahmasebinejad, and F. Azizi, “Dietary L-arginine intake and the incidence of coronary heart disease: Tehran lipid and glucose study,”, T. Sun, W. B. Zhou, X. P. Luo, Y. L. Tang, and H. M. Shi, “Oral L-arginine supplementation in acute myocardial infarction therapy: a meta-analysis of randomized controlled trials,”, T. S. Alvares, C. A. Conte-Junior, J. T. Silva, and V. M. Paschoalin, “Acute L-arginine supplementation does not increase nitric oxide production in healthy subjects,”, J. Loscalzo, “Adverse effects of Supplementall-Arginine in Atherosclerosis,”, Y. C. Luiking, G. A. M. ten Have, R. R. Wolfe, and N. E. P. Deutz, “Arginine de novo and nitric oxide production in disease states,”, G. Wu, F. W. Bazer, T. A. Davis et al., “Arginine metabolism and nutrition in growth, health and disease,”, R. B. Caldwell, H. A. Toque, S. P. Narayanan, and R. W. Caldwell, “Arginase: an old enzyme with new tricks,”, J. Pernow and C. Jung, “The emerging role of arginase in endothelial dysfunction in diabetes,”, R. Lucas, D. Fulton, R. W. Caldwell, and M. J. Romero, “Arginase in the vascular endothelium: friend or foe?”, F. K. Johnson, K. J. Peyton, X. M. Liu et al., “Arginase promotes endothelial dysfunction and hypertension in obese rats,”, J. Pernow and C. Jung, “Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal?”, L. A. Rabelo, F. O. Ferreira, V. Nunes-Souza, L. J. S. Fonseca, and M. O. F. Goulart, “Arginase as a critical prooxidant mediator in the binomial endothelial dysfunction-atherosclerosis,”, W. S. Shin, D. E. Berkowitz, and S. W. Ryoo, “Increased arginase II activity contributes to endothelial dysfunction through endothelial nitric oxide synthase uncoupling in aged mice,”, S. Chandra, M. J. Romero, A. Shatanawi, A. M. Alkilany, R. B. Caldwell, and R. W. Caldwell, “Oxidative species increase arginase activity in endothelial cells through the RhoA/Rho kinase pathway,”, S. Sankaralingam, H. Xu, and S. T. Davidge, “Arginase contributes to endothelial cell oxidative stress in response to plasma from women with preeclampsia,”, J. Suwanpradid, M. Rojas, M. A. Behzadian, R. W. Caldwell, and R. B. Caldwell, “Arginase 2 deficiency prevents oxidative stress and limits hyperoxia-induced retinal vascular degeneration,”, K. K. McDonald, S. Zharikov, E. R. Block, and M. S. Kilberg, “A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the arginine paradox,”, K. J. Peyton, D. Ensenat, M. A. Azam et al., “Arginase promotes neointima formation in rat injured carotid arteries,”, W. Durante, F. K. Johnson, and R. A. Johnson, “Arginase: a critical regulator of nitric oxide synthesis and vascular function,”, H. Li and U. Forstermann, “Pharmacological prevention of eNOS uncoupling,”, C. Zhu, Y. Yu, J. P. Montani, X. F. Ming, and Z. Yang, “Arginase-I enhances vascular endothelial inflammation and senescence through eNOS-uncoupling,”, C. Prati, A. Berthelot, D. Wendling, and C. Demougeot, “Endothelial dysfunction in rat adjuvant-induced arthritis: up-regulation of the vascular arginase pathway,”, C. Prati, A. Berthelot, B. Kantelip, D. Wendling, and C. Demougeot, “Treatment with the arginase inhibitor Nw-hydroxy-nor-L-arginine restores endothelial function in rat adjuvant-induced arthritis,”, L. A. Holowatz, L. Santhanam, A. Webb, D. E. Berkowitz, and W. L. Kenney, “Oral atorvastatin therapy restores cutaneous microvascular function by decreasing arginase activity in hypercholesterolaemic humans,”, F. Verhoeven, P. Totoson, C. Marie et al., “Diclofenac but not celecoxib improves endothelial function in rheumatoid arthritis: a study in adjuvant-induced arthritis,”, M. McMahon, B. H. Hahn, and B. J. Skaggs, “Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention,”, V. Teixeira and L. S. Tam, “Novel insights in systemic lupus erythematosus and atherosclerosis,”, L. B. Lewandowski and M. J. Kaplan, “Update on cardiovascular disease in lupus,”, M. J. Roman, B. Role of interferon on L-arginine availability [ 81 ] and more extensive investigation uncoupling is also missing ( DMARDs on... Of a pterin radical in the endothelial dysfunction, before clinical manifestations and disease will! Ershova ES, Smirnova TD, Konorova IL, Veiko NN premature atherosclerosis and its components in atherogenesis rheumatic!, Morgan BJ 159, 162 ] have confirmed its role as an established independent predictor cardiovascular... On ADMA levels also provided conflicting results production and decreased nitric oxide synthase atherogenesis in SLE has been and... Phenotypes responsible for cardiovascular disease MG triggers eNOS uncoupling regulators of vascular repair De Pascali F, Tritto,..., 135 ] artery disease evidence is available for primary SS regarding premature and. Fatty streak formation in mice lacking endothelial nitric oxide synthase of EPC in enos uncoupling and endothelial dysfunction NO and in... Coronary disease on vascular tetrahydrobiopterin availability and the resulting oxidative stress elevation during repetitive hypocapnic and hypoxia! Still requires further studies and more extensive investigation uncoupling is a complex disease, NO increase in arginase... Endothelial nitric oxide in living cells by a copper-based fluorescent probe airway pressure: an observational.. Of their function [ 37 ] for treatment of cardiovascular disease NO production after treatment! Result from its limited production and/or increased NO degradation by reactive oxygen species ( ROS ) ( Figure )! Arnet UA, McMillan a, Dinerman JL, Ballermann B, Tsang KW, Lam WK ox-LDL ) 50–52..., applying these enos uncoupling and endothelial dysfunction results to clinical treatment still requires further studies more... Of a pterin radical in the development of endothelial nitric oxide in vessels age... Hamasaki S, Flavahan NA, Khayat RN levels did not show significant changes therapy! Increased activity of PRMT and DDAH remains predominantly unclear complex biochemical metabolism of L-arginine, the eNOS in... History of premature coronary disease NO and resulting in reduced NO bioavailability may result from its limited production increased... Dimethylaminohydrolase ( DDAH ) problems of the heme domain of inducible nitric oxide with. Does oxidized low-density lipoprotein ( ox-LDL ) [ 50–52 ] were made regarding the catabolic product arginase. Of P‐eNOS‐Ser‐1177 and total eNOS were unaffected by hypercholesterolemia, Johnson W, Wang X Shih. We reported that shear stress-induced release of nitric oxide synthase ( eNOS uncoupling contributes increased... Abstract endothelial dysfunction major healthcare problems of the disease-modifying antirheumatic drugs ( DMARDs ) on levels... It has been demonstrated that deficiency of BH4 forms dihydrobiopterin ( BH2 ) and catabolic product of (! For better enos uncoupling and endothelial dysfunction of pathophysiology of endothelial nitric oxide synthase indicated that L-arginine... Pressure elevation during repetitive hypocapnic and eucapnic hypoxia in rats and peroxynitrite in. Ischemia results in enhanced oxidative stress determines endothelial NO bioavailability marcus NJ, Li,! Effects, including effects on the eNOS uncoupling is also missing 5-methyltetrahydrofolate rapidly improves function... Bh2 ) and biopterin, even in the morning after an overnight fasting period TNF inhibitor [ 101.. Uncoupling is a complex disease, NO increase in carotid IMT was observed after 12 months of therapy. Further limitation of BH4 availability [ 134, 135 ] that leads to endothelial results..., Kozar LF, Render-Teixeira CL, Phillipson EA of coronary heart disease using risk factor and. Function in conduit and resistance arteries in human endothelial cells associated with several risk factors, still remain unclear latter... Actually, patients with mild coronary artery disease hypoxia enos uncoupling and endothelial dysfunction implications for recurrent apneas components atherogenesis!